Story thread · 2 reports / 2 sources
Corcept targets $1.1B-$1.2B 2026 revenue as Lifyorli launch reaches 1,300 patients and relacorilant awaits Dec. 17 PDUFA
seekingalpha.com · 12d
First report: Corcept earnings on deck as Lifyorli launch faces scrutiny — investing.com, 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.